Vistagen Therapeutics, Inc. (VTGN)
0.2739
-0.02
(-7.15%)
USD |
NASDAQ |
Sep 25, 16:00
0.263
-0.01
(-3.98%)
After-Hours: 19:59
Vistagen Therapeutics Research and Development Expense (Annual) : 54.78M for March 31, 2026
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| March 31, 2026 | 54.78M |
| March 31, 2025 | 39.38M |
| March 31, 2024 | 20.02M |
| March 31, 2023 | 44.28M |
| March 31, 2022 | 35.31M |
| March 31, 2021 | 12.41M |
| March 31, 2020 | 13.33M |
| March 31, 2019 | 17.05M |
| March 31, 2018 | 7.696M |
| March 31, 2017 | 5.167M |
| Date | Value |
|---|---|
| March 31, 2016 | 3.895M |
| March 31, 2015 | 2.389M |
| March 31, 2014 | 2.437M |
| March 31, 2013 | 2.613M |
| March 31, 2012 | 5.251M |
| March 31, 2011 | 3.633M |
| December 31, 2009 | 0.00 |
| December 31, 2008 | 0.00 |
| December 31, 2007 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Onconetix, Inc. | -0.0661M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |